Noubar Afeyan, a prominent biotech investor, has warned that opposition to science in the US could threaten biotech innovation.[1] Afeyan is co-founder of Moderna and founder and CEO of venture capital firm Flagship Pioneering.[3] Flagship Pioneering has developed more than 100 scientific projects with a total value of more than 100 billion dollars, thousands of patents and more than 50 drugs in clinical development.[3] Afeyan has founded or co-founded over 100 life sciences and technology startups.[3] In 2021, he announced that Moderna would not pursue its patents for the production of vaccines against COVID-19.[1] In 2025, he won the National Medal for Technology and Innovation.[1] Afeyan holds a PhD in Biochemical Engineering from MIT in 1987 and holds over 100 patents.[2] In the Pharmalittle article, he also covers the topics of longevity medicine and other innovations. [original content]